Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
Certain CTDs can hurt more than just the skin. They can also hurt the body's organs and joints. A lot of different things can change the market trends for these illnesses. These variables include the number of persons with connective tissue disorders, the progress achieved in detecting them, the diversity of treatments available, and rheumatology research. People now realize how common and varied connective tissue illnesses are. To manage rheumatoid arthritis, systemic lupus erythematosus, and scleroderma, many diagnostic and treatment methods must be used. New ways to find diseases of the joint tissues are made every once in a while. The market is changed by these new ideas. There are changes in the market because of all of these. There are several ways that doctors might be able to find and identify diseases faster and more accurately. Biomarkers have been found, imaging methods have been made better, and all blood tests are now complete. The best way to change care for a chronic repeated illness (also known as CTD) is to make sure the right diagnosis is made first. The changes in the market that happen when new drugs for muscles come out are the fault of drug makers. DMARDs, biologics, and focused care are all thought to help ease symptoms and slow the development of the illness. It is the job of research and development to make it simple to find better and safer ways to treat symptoms. To sell CTD, the release of immunomodulatory drugs is given a lot of weight. In healthy persons, antibodies that impair the immune system may also affect it. These medications help reduce edema and mend cells, which is fantastic. Better connective tissue disease treatments are excellent for patients. The two are related, and rheumatologists may work. Rheumatologists diagnose and treat joint disorders best. The way resources are shared in the healthcare system has changed because of how arthritis is healed. Plans to treat connective tissue disease that focus on the wants and needs of people who have the illness can help rebuild markets. This is done while care plans are being made. People who get healthcare solutions that are made just for them are happy and more likely to keep using them. Biology and genetics research is revealing the basic pathways that underlie connective tissue illnesses. Genetic information transforms markets and allows for patient-specific treatment strategies and drugs. Connective tissue disease education and empowerment initiatives are well received by the market. Disease patients feel more connected and get better treatment via awareness, support, and education. Medicine safety and acceptability regulations affect the market. Following laws, having new pharmaceuticals authorized, and healthcare standards affect how simple it is to receive and utilize new connective tissue disease therapies. Healthcare developments including telemedicine, digital health data, and remote tracking affect the industry. These innovations make connective tissue disease care simpler to access and maintain. Research and clinical trials teach us about connective tissue disorders and test novel medicines, changing the market. Pharmaceutical companies, research schools, and healthcare personnel collaborate to innovate.
Connective Tissue Disease Market Highlights:
Connective Tissue Disease Market Scenario
The Connective Tissue Disease Market is anticipated to reach USD 3,851.14 Million by 2030 at 11.5% CAGR during the forecast period 2022-2030. Connective tissues are a group of cellular congregations that provide support and structure to the human body. Connective tissue disease is a group of disorders which involves these protein rich tissues. Protein rich tissues play an important role of supporting organs and other parts of the body. Connective tissue disorders involves multiple organs and organ systems such as, skin, joints, muscles, lungs, kidneys, eyes, heart, gastrointestinal tract, and blood vessels. More than 200 disorders affect the connective tissues. According to a study published in Pan African Medical Journal in 2017, it is found that mixed connective tissue disorders are more frequent among Asians, and in the African population. It is also reported that among Asian population, the condition is more prevalent in China, and Japan. In the European region, the disorder is more prevalent in Italy, Hungary, Norway, and Poland.
The specific cause of this disorder is unknown but the genetic patterns are considered to escalate the risk for developing connective tissue diseases. The connective tissue diseases arises due to changes in certain genes are often known as heritable disorders of connective tissue. Some of the common inherited disorders are Ehlers-Danlos syndrome (EDS), Epidermolysis bullosa (EB), Marfan Syndrome, and Osteogenesis imperfect. EDS is an amalgamation of more than 10 disorders, characterized by stretchy skin, over-flexible joints, and abnormal growth of scar tissue. Various autoimmune diseases are also associated with connective tissue disorders, which includes polymyositis and dermatomyositis, rheumatoid arthritis (RA), Sjögren's syndrome, and vasculitis. Mixed connective tissue disease (MCTD) is another rare autoimmune disease, consisting of characteristic features of several diseases such as lupus, polymyositis or dermatomyositis, scleroderma, and rheumatoid arthritis. According to the National Center for Advancing Translational Medicines, currently there is no cure available for this condition but certain medications such as corticosteroids, immunosuppresive drugs, and nonsteroidal anti-inflammatory drugs (NSAIDs) help in the management of symptoms. It is also stated that MCTD is more frequent in females with a male to female ratio of 1:3, and the typical age of onset of MCTD is between 15-25 years.
Notably, the Connective Tissue Disease Market is expected to expand in the near future due to the rising prevalence of various connective tissue disorders, high unmet needs of current treatment, and surge in the research and development expenditure.
Despite these drivers, there are some issues associated with connective tissue disease market. Lack of infrastructure in the middle and low income countries may hamper the growth of the market.
Intended Audience
- Hospitals
- Diagnostic clinics
- Research and Development (R&D) Companies
- Government Research Institute
- Academic Institutes and UniversitiesÂ
Figure: Global Connective Tissue Disease Market, By Region Market Share, 2017 (%) 
Sources: Annual reports, Press release, White paper, Company presentation
Segmentation
The connective tissue disease market is segmented on the basis of diagnosis, treatment, and end-user.
On the basis of diagnosis, market is segmented into physical examination, X-ray examination, ANA (Antinuclear Antibody Test), and others.
On the basis of treatment, market is classified into non-steroidal anti-inflammatory drugs (NSAIDs), cortisone drugs/steroids, antimalarial drugs, cytotoxic drugs, and others
On the basis of end-user, market is segmented into hospital, diagnostic clinics, and others.
Regional Analysis
The Americas dominate the connective tissue disease market owing to the rising awareness among people, and increasing healthcare expenditure. As per the facts suggested by the Centers for Disease Control and Prevention (CDC), out of the total annual healthcare expenditure, 86% is for people with chronic health conditions in the United States.
Europe holds the second position in the connective tissue disease market. It is expected that the support provided by government bodies for research & development and improvement in reimbursement policies in healthcare will drive the Connective Tissue Disease Market in Europe.
Asia Pacific is the fastest growing Connective Tissue Disease Market, owing to a huge patient pool, developing healthcare technology, and rising healthcare expenditure in some countries within this region. According to the Australian Institute of Health and Welfare, in the years 2015 to 2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than expenditure of 2014–15.
The Middle East & Africa has the lowest Connective Tissue Disease Market due to lack of technical knowledge and poor medical facilities.Â
Key Players
Some of key the players in the Connective Tissue Disease Market are Abbott Laboratories, Bayer AG, F. Hoffmann-La Roche Ltd, Pfizer, AutoImmune Inc., Johnson & Johnson, Amgen Inc., AstraZeneca, Eli Lilly and Company, Biogen, LUPIN, and others.
Research Methodology
Sources: Annual reports, Press release, White paper, and Company presentation
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
